LT-1339–553: Potent RIPK1 Inhibitor Data for Hepatic Fibrosis

LT-1339–553 is a potent RIPK1 inhibitor with an IC50 of 4.32 nM and cellular EC50 of 14.43 nM. This dataset, uploaded by Ju-Lu Lu in May 2026, contains results from a murine model showing the compound's efficacy in reducing liver injury, inflammation, and collagen deposition. Mechanistic data suggests its effects involve suppression of the AKT/PI3K/NF-κB and IL-17 pathways.

Use Cases

• Evaluating in vitro potency of RIPK1 inhibitors based on reported IC50 and EC50 values
• Assessing in vivo efficacy for liver fibrosis treatment based on murine model results
• Studying mechanistic pathways of antifibrotic compounds based on the AKT/PI3K/NF-κB and IL-17 pathways mentioned
• Comparing pharmacokinetic profiles of drug candidates based on reported oral bioavailability and safety data

Strengths

• Includes specific potency metrics (IC50 = 4.32 nM, EC50 = 14.43 nM)
• Describes results from an in vivo murine model of hepatic fibrosis
• Contains mechanistic study data on relevant signaling pathways

Limitations

• Dataset is very small (2.5 KB), indicating limited scope
• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment

Provenance

Source

figshare

Collection Method

Likely contains results from structure-based drug optimization and preclinical animal studies.

Freshness

Last updated 2026-05-16 14:09:42; freshness should be verified